Abed Rahman Kawakibi, MD
@abedkawakibi
PGY-2 @UChicagoRadonc | via @UMichSurgery, @UMichMedicine, @UCLA | Committed to improving healthcare for the underrepresented
ID: 1198274793008594946
23-11-2019 16:19:15
56 Tweet
254 Followers
295 Following
Honored and grateful to be named as one of the Rogel Scholarship recipients for this year. Big thanks to Carl Koschmann, Koschmann Lab, and @jallenphd for the mentorship over the years, and to U-M Rogel Cancer Center and the Rogel family for this privilege.
Another article highlighting our recent paper led by Evan Cantor tracking treatment response and tumor progression via liquid biopsy of CSF and plasma #DIPG clinicalresearchnewsonline.com/news/2022/05/1…
A $1 million gift from Yuvaan Tiwari Foundation Foundation will accelerate brain tumor research led by Michigan Medicine’s Carl Koschmann, MD. Inspired by Yuvi who died of a diffuse midline glioma at age 3, the foundation offers hope to families facing cancer. michmed.org/PXRYN
The students at @UMichMedAdmiss are what makes Michigan Medicine such an amazing place to work. Student led initiatives like Medical Arabic @ UMMS which aims to teach Medical Arabic to ensure equitable access for all of our patients is just one example… #GoBlue!〽️ AAMC ACGME
Abed Rahman Kawakibi, MD Day ☝🏾s forever, 🤝🏾💪🏾proud of you doc!
November issue— Clinical efficacy of ONC201 in H3K27M-#DMG, by Vennetilab, Abed Rahman Kawakibi, MD, Sunjong Ji, Sebastian Waszak, Stefan Sweha, Mateus Mota, Matthew Pun, Sharon Gardner, Yazmin Odia, Koschmann Lab et al. bit.ly/3QZMhKv Michigan Medicine U-M Rogel Cancer Center C.S. Mott Children's #DIPG
UChicago Medicine We also want to give a shout out to the residents from the class of 2028 who will be joining us this summer: Abed Rahman Kawakibi, Sophia Kim-Wang, and Ryan Zitter! #match2024 #RadOnc #GME #matchday2024
Check out the latest from UChicagoCancerCenter HN Group - the DEPEND trial. 1) There is strong interest in determining how to incorporate immunotherapy into non-operative management for LA-HNSCC to improve outcomes for high risk HPV-negative patients.
Honored to be on Capitol Hill advocating for the bipartisan ROCR Act and meaningful reforms to prior authorization—advancing patient care through smarter policy. TaritaThomas MD, PhD, MBA Eric Donnelly John White ASTRO ARRO
For the first time, the FDA has approved a drug, ONC201, for diffuse midline gliomas. Carl Koschmann (Carl Koschmann) answers questions about the U-M research that led to the approval and what it means for patients. Link: michmed.org/WXd3Z
Very grateful for the opportunity and the great mentorship at University of Chicago Radiation Oncology. Special thanks to Rohan Katipally for all the support!